## PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: Mail Mail Stop ISSUE FEE Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 or Fax (571) 273-2885

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as address as minicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)

9629 7590 07/12/2010

Morgan, Lewis & Bockius LLP 1111 Pennsylvania Avenue, N.W. Washington, D.C. 20004

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

Certificate of Mailing or Transmission

I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO (571) 273-2885, on the date indicated below.

Depositor's nam (Stenatu (Date ATTORNEY DOCKET NO. CONFIRMATION NO.

APPLICATION NO FILING DATE FIRST NAMED INVENTOR 10/572,794 03/21/2006 Bernard Christophe Barlaam 056291-5245 4231

TITLE OF INVENTION:

QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS

APPLN. I YPE	SMALL EN III Y	ISSUE P	EE	PUBLICATION FEE	TOTAL	EE(S) DUE DATE DUE		
nonprovisional	NO	\$151	ס	\$300	\$	1810	10/12/2010	
EXA	MINER	ART UN	IT	CLASS-SUBCLASS	]			
Truong, Ta	mthom Ngo	1624		514-266200	_			
1. Change of correspondence address or indication of "Fee Address" (37 CFR 1363).  Change of correspondence address (or Change of Correspondence Address from FTO SB 122) attached.  "Fee Address" indication (or "Fee Address" Indication form FTO SB 47; Rev 03-02 or more recent) attached. Use of a Customer Number is required.			2. For printing on the patent front page, list (1) the names of up to 3 registered patent attorneys or agents OR, alternatively, (2) the name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed.			1_Morgan, Lewis & 2_Bockius LLP		
PLEASE NOTE: Unles	D RESIDENCE DATA TO E s an assignee is identified b n 37 CFR 3.11. Completion	elow, no assignee	data will apr	pear on the patent. If an assign	nee is identifi	ed below, the d	ocument has been filed for	

(A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY) AstraZeneca AB Sodertalie, Sweden

	•				
Please check the appropriate assignee category or categories (will not b	pe printed on the patent):	☐ Individual	☑ Corporation or other private	group entity	Government
a. The following fee(s) are enclosed:	4b. Payment of Fee(s):				
☑ Issue Fee	A check in the an	ount of the fee(s	s) is enclosed.		
☑ Publication Fee (No small entity discount permitted)	Payment by credi	t card. Form PTC	0-2038 is attached.		
Advance Order - # of Copies	The Director is h Deposit Account Nur		d by charge the required fee(s), 0-0310	or credit any	overpayment, to

5. Change in Entity Status (from status indicated above)

a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27. ■ b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2).

The Director of the USPTO is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above. NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Trademark Office.

Authorized Signature /Donald Bird/ Date October 12, 2010 Typed or printed name Donald J. Bird Registration No. 25,323

This collection of information is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) Insconlication of informations is required by 37 CFR, 13.11. In information is required to obtain or retain a benefit by the public winch is to lite (and by the USF 10 to process) an application. Confidentially is possible, including gathering, pressuring, and application. Confidentially is possible including gathering, pressuring, and in the confidential process of the confidential process. The confidential process of Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.